Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
ABT.MX

Price
1937.00
Stock movement down
-2.03 (-0.10%)
Company name
Abbott Laboratories
Exchange
(MX
,
Currency
MXN
)
Sector
Healthcare >
Medical Devices
Market cap
3471.84B
Ent value
3497.26B
Price/Sales
78.32
Price/Book
65.79
Div yield
-
Div growth
-
Growth years
-
FCF payout
55.66%
Trailing P/E
532.16
Forward P/E
-
PEG
-
EPS growth
8.16%
1 year return (CAGR)
-28.13%
3 year return (CAGR)
2.72%
5 year return (CAGR)
-4.03%
10 year return (CAGR)
19.40%
Last updated: 2026-03-11

DIVIDENDS

ABT.MX does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E532.16
Price to OCF362.94
Price to FCF469.48
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales78.32
Price to Book65.79
EV to Sales78.89

FINANCIALS

Per share

Loading...
Per share data
Current share count1.74B
EPS (TTM)3.76
FCF per share (TTM)4.26

Income statement

Loading...
Income statement data
Revenue (TTM)44.33B
Gross profit (TTM)25.01B
Operating income (TTM)8.05B
Net income (TTM)6.52B
EPS (TTM)3.76
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)56.42%
Operating margin (TTM)18.17%
Profit margin (TTM)14.72%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash8.52B
Net receivables7.93B
Total current assets26.00B
Goodwill24.04B
Intangible assets5.53B
Property, plant and equipment25.22B
Total assets86.71B
Accounts payable4.24B
Short/Current long term debt0.00
Total current liabilities16.50B
Total liabilities33.94B
Shareholder's equity52.77B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)9.57B
Capital expenditures (TTM)2.17B
Free cash flow (TTM)7.39B
Dividends paid (TTM)4.12B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.36%
Return on Assets7.52%
Return on Invested Capital10.41%
Cash Return on Invested Capital11.80%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1997.97
Daily high1997.97
Daily low1997.97
Daily Volume1K
All-time high2930.00
1y analyst estimate-
Beta0.74
EPS (TTM)3.76
Dividend per share0.00
Ex-div date15 Jan 2026
Next earnings date15 Apr 2026

Downside potential

Loading...
Downside potential data
ABT.MXS&P500
Current price drop from All-time high-33.89%-1.82%
Highest price drop-77.41%-56.47%
Date of highest drop23 Nov 20129 Mar 2009
Avg drop from high-18.02%-10.84%
Avg time to new high8 days12 days
Max time to new high1118 days1805 days
COMPANY DETAILS
ABT.MX (Abbott Laboratories) company logo
Marketcap
3471.84B
Marketcap category
Large-cap
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Employees
115000
Investor relations
-
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
If you are wondering whether Abbott Laboratories is offering fair value at around US$112.65 per share, you are not alone. This article is designed to help you make sense of what that price might reall...
March 10, 2026
Abbott (ABT) reached $112.65 at the closing of the latest trading day, reflecting a +2.82% change compared to its last close.
March 9, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
March 9, 2026
Over the past six months, AbbVie has been a great trade, beating the S&P 500 by 5.6%. Its stock price has climbed to $233.25, representing a healthy 11.2% increase. This was partly thanks to its solid...
March 6, 2026
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
March 6, 2026
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.
March 6, 2026
Shanghai Henlius Biotech (SEHK:2696) has drawn fresh investor attention after revising its licensing arrangements with Abbott, expanding rights for a key product to 42 additional countries and setting...
March 5, 2026
The Balloon Catheter market is projected to grow from $5.04 Billion in 2025 to $8.51 Billion by 2033, driven by a CAGR of 6.75%. This growth stems from increased cardiovascular disease cases and deman...
March 5, 2026
Discover the leading players and innovations shaping the global biosensors market with the "Biosensors Companies Quadrant" report by 360 Quadrants. This comprehensive industry analysis evaluates over ...
March 5, 2026
LONDON & PENSACOLA, Fla., March 05, 2026--Reckitt Benckiser (LON: RKT) subsidiary Mead Johnson is facing a bellwether trial in the US Multidistrict Litigation (MDL) over infant formula product Enfamil...
March 5, 2026
Next page